Please note that the evaluation of trastuzumab deruxtecan for treating HER2-mutated unresectable or metastatic non-squamous non-small-cell lung cancer after 1 or more therapies ID3934, will now be conducted via ID6234 considering multiple treatments for non-small-cell lung cancer.